Caplin Point Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 524742 | NSE: CAPLIPOINT | Pharmaceuticals & Drugs | Small Cap

Caplin Point Lab Share Price

1,330 70.05 5.56%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Caplin Point Lab

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Caplin Point Laboratories stock performance -

mw4me loader
P/E Ratio (CD):
21.86
Market Cap:
9,568.3 Cr.
52-wk low:
575
52-wk high:
1,617.8

Is Caplin Point Laboratories Ltd an attractive stock to invest in?

1. Is Caplin Point Laboratories Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Caplin Point Laboratories Ltd is a average quality company.

2. Is Caplin Point Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Caplin Point Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Caplin Point Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Caplin Point Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Caplin Point Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Caplin Point Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Jun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 50.3%54.2%42.5%52.7%47.8%33.9%24.1%22.3%21.4%21.5%-
Value Creation
Index
2.62.92.02.82.41.40.70.60.60.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1732523184025406498631,0611,2691,4671,630
Sales YoY Gr.-45.5%26.4%26.2%34.4%20.2%33.1%23%19.6%15.5%-
Adj EPS 3.75.78.412.418.622.325.932.438.648.457.6
YoY Gr.-53.2%48.5%46.9%50.2%20%16.1%25.2%18.9%25.5%-
BVPS (₹) 7.711.821.729.747.778114.2144.9183.9235.9288.8
Adj Net
Profit
2842.963.693.5141169196245292367438
Cash Flow from Ops. 59.849.956.567.666.583.444.7269337271-
Debt/CF from Ops. 0.100.10000.80.100-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 26.8%22.1%19.3%15.5%
Adj EPS 33.1%21.1%23.2%25.5%
BVPS46.3%37.7%27.4%28.3%
Share Price 43.1% 27.1% 47.4% 127.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Jun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
53.455.343.15347.733.824.82321.921.822
Op. Profit
Mgn %
22.724.828.131.236.235.730.13131.130.132.5
Net Profit
Mgn %
16.217.12023.3262622.72423.725.126.9
Debt to
Equity
0.1000000000-
Working Cap
Days
6147716795133176197211227181
Cash Conv.
Cycle
-57-49-68-51-19331121159496150

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 19.33%

Net Profit is growing at healthy rate in last 3 years 23.16%

Sales growth is good in last 4 quarters at 15.04%

Return on Equity has declined versus last 3 years average to 22.00%

Latest Financials - Caplin Point Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 35.3 57.6
TTM Sales (₹ Cr.) 630 1,630
BVPS (₹.) 174 288.8
Reserves (₹ Cr.) 1,306 2,178
P/BV 7.24 4.36
PE 35.68 21.86
From the Market
52 Week Low / High (₹) 575.00 / 1617.80
All Time Low / High (₹) 0.18 / 1617.80
Market Cap (₹ Cr.) 9,568
Equity (₹ Cr.) 15.2
Face Value (₹) 2
Industry PE 47.8

Management X-Ray of Caplin Point Lab:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Caplin Point Lab

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSJun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales1732522394025406498631,0611,2691,467
Operating Expenses 1371921752773454176037378751,026
Manufacturing Costs1025223848578386103117
Material Costs103136121185238289413472558663
Employee Cost 13181830384667102115136
Other Costs 111414242125407799110
Operating Profit 366064125195232260324395441
Operating Profit Margin (%) 20.9%23.7%26.9%31.1%36.2%35.7%30.1%30.6%31.1%30.0%
Other Income 43410131941283957
Interest 1101110211
Depreciation 48713192332374745
Exceptional Items 0000000000
Profit Before Tax 365360121188227269314386451
Tax 10121425445054627774
Profit After Tax 26414696145177215251308377
PAT Margin (%) 15.0%16.3%19.2%23.8%26.8%27.2%24.9%23.7%24.3%25.7%
Adjusted EPS (₹)3.45.46.112.719.223.328.432.039.649.6
Dividend Payout Ratio (%)23%18%20%12%10%9%9%9%10%9%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSJun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 62931272253616269381,1711,4681,865
Share Capital 15151515155190909090
Reserves 47781112103455758491,0811,3791,775
Minority Interest0000009182627
Debt2110000013
Long Term Debt2110000000
Short Term Debt0000000013
Trade Payables3242567994606489156164
Others Liabilities 8493845445561148779118
Total Liabilities 1802292673585007431,1261,3641,7302,178

Fixed Assets

Gross Block123143181195232272355423446480
Accumulated Depreciation21303743624582117159201
Net Fixed Assets102113144152169227273305287280
CWIP 2531031510201418221
Investments 000174770611189230
Inventories101419222837238179227288
Trade Receivables06833126160229279317394
Cash Equivalents 2745689379153223438463493
Others Assets16202737358682136329272
Total Assets 1802292673585007431,1261,3641,7302,178

Cash Flow

(All Figures are in Crores.)
PARTICULARSJun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 60504268668345269337271
PBT 365360121188227269314386451
Adjustment 264915197233012
Changes in Working Capital 292-5-38-100-120-177-22-104
Tax Paid -7-12-16-24-36-43-55-66-81-88
Cash Flow From Investing Activity -44-23-6-36-69-100-55-29-377-218
Capex -47-25-8-25-49-65-77-73-91-193
Net Investments 100-17-27-201024-200-49
Others 23267-151320-8525
Cash Flow From Financing Activity -6-9-14-7-129080-24-41-28
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -1-100000-19-173
Interest Paid 0000000-2-1-1
Dividend Paid -4-7-14-6-11-15-33-3-23-30
Others 000001051130-10
Net Cash Flow 10192325-147370215-8126
PARTICULARSJun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)53.2455.7843.1354.9749.4337.1429.5825.6524.7723.68
ROCE (%)68.9971.1155.4169.0364.0845.5933.3528.8228.7726.85
Asset Turnover Ratio1.11.230.961.281.261.040.920.850.820.75
PAT to CFO Conversion(x)2.311.220.910.710.460.470.211.071.090.72
Working Capital Days
Receivable Days141019548082878688
Inventory Days21172519171958725864
Payable Days102981471331329855598088

Caplin Point Laboratories Ltd Stock News

Caplin Point Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Caplin Point Lab on 28-Mar-2024 16:01 is ₹1,330.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Caplin Point Lab stood at ₹9,568.3.
The latest P/E ratio of Caplin Point Lab as of 28-Mar-2024 16:01 is 35.68.
The latest P/B ratio of Caplin Point Lab as of 28-Mar-2024 16:01 is 7.24.
The 52-week high of Caplin Point Lab is ₹1,617.8 and the 52-week low is ₹575.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Caplin Point Lab is ₹630.4 ( Cr.) .

About Caplin Point Laboratories Ltd

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.

The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.

Business area of the company

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

Products

  • Liquid Injections
  • Lyophilised Injections
  • Opthalmic
  • Tablets
  • Liquid Orals
  • Capsule
  • Softgel Capsules
  • Suppositories & Ovules
  • Powder for Injection
  • Dry syrup
  • Topicals
  • Liquid Injections
  • Inhalers
  • Ophthalmic
  • IV Infusion
  • Lyophilised Products
  • Branded Products
  • Dermo Cosmetics

Awards and recognitions

  • 2014: Forbes Asia Best under a Billion Award - 2014.
  • 2015: Forbes Asia Best under a Billion Award - 2015.
  • 2016: Forbes Asia Best under a Billion Award - 2016.
  • 2017: Nanayam Vikatan’s Gold Phoenix Award to Mr. C C Paarthipan.
  • 2017: Financial express CFO Awards 2017 (Second Rank).
  • 2017: IPF’s industrial Excellance Award.
  • 2018: The Economic Times - Family Business of the year Award.
  • 2018: Pharmexcil Outstanding Exports Award 2018.
  • 2018: The Economic Times Award for Excellence in Business Performance.
  • 2019: Empowering India Awards 2019 in Pharmaceutical, Healthcare and Bio-Technology Segment.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.